Mechanisms and Implications of Age-Related Changes in the Liver: Nonalcoholic Fatty Liver Disease in the Elderly
Open accessThe DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis associated with metabolic abnormalities such as overweight/central obesity, insulin resistance, type 2 diabetes (T2D), and dyslipidemia. NAFLD is becoming the most common liver disease in contemporary society, with the highest prevalence in those over 60 years. NAFLD pathology ranges from simple steatosis to a necroinflammatory fibrosing disorder called steatohepatitis (SH), the latter associated with high risk of developing cirrhosis, often occuring in the seventh to ninth decades of life. While the main health implications of NAFLD are increased risk of developing T2D, cardiovascular diseases, and common cancers, there is substantantially increased standardized mortality, and deaths from decompensated cirrhosis and hepatocellular carcinoma (HCC). Little is known about the interactive effects of ageing and NAFLD, with most studies focusing on the younger population. This paper summarises the epidemiology, pathogenesis, and clinical course of NAFLD, with particular attention to persons over age 60 years. An approach to the management of NASH and its complications in the elderly, will also be presented here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Mechanism of hepatic steatosis, adapted from Larter et al. 2010 [12], showing also interactions between adipose tissue in differing sites with liver in the development of insulin resistance (IR). FFA: free fatty acids; SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue; TG: triglyceride.](https://figures.cochat.ai/paper-figures/0dead70903384916b109d67f64dbc328/mechanisms-and-implications-of-age-related-changes-in-the-liver-nonalcoholic-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, with age, the decline in WAT mass is associated with accumulation of fat in ectopic regions in non-adipose tissue organs like skeletal muscle (34), liver (35), and bone marrow (36), which exacerbates metabolic dysfunction (37).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Angelico, F., Burattin, M., Alessandri, C., Del Ben, M., & Lirussi, F. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005166.pub2 · Cited by 114
RetractedGrundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326 · cited 1×
“As discussed earlier, the accompanying hyperinsulinemia promotes de novo hepatic lipogenesis [79], further promoting lipid overload in hepatocytes.”
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Rosiglitazone has been withdrawn from the European market due to increased rates of myocardial infarction, but not overall cardiovascular mortality in a meta-analysis of approximately 35,000 patients from 56 randomised controlled trials [112].”
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · cited 3×
“An older concept of NASH pathogenesis, the so-called “two-hit” hypothesis of Day and James [58], proposed that hepatocyte TG accumulation resulting from metabolic imbalance (obesity, IR and diabetes) is what leads to steatosis (the “first hit”) and that the lipid-laden liver is then vulnerable to injurious processes (…”
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“In the elderly population, TE is a promising noninvasive method of quantifying liver fibrosis in NAFLD.”
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“Kinetic studies indicate that approximately 75% of hepatic lipids (TAG/TG) in obese patients with NAFLD comes from peripheral sites (60% from nonesterified free fatty acids from lipolysis and 15% from diet), with approximately 25% arising from de novo lipogenesis [68].”
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890 · cited 1×
“In multivariate analysis, age, BMI, arterial hypertension, ALT, insulin resistance, and hepatic necroinflammatory grade were shown to independently predict presence of fibrosis [27, 36, 57, 86, 87, 89, 91].”
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“In multivariate analysis, age, BMI, arterial hypertension, ALT, insulin resistance, and hepatic necroinflammatory grade were shown to independently predict presence of fibrosis [27, 36, 57, 86, 87, 89, 91].”
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,414 · cited 2×
“Also, with regards to the older patient with NAFLD, TZDs can precipitate heart failure and their use is not recommended for patients with New York Heart Association Class III and IV heart failure [67, 111].”
Self-citationLong-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148 · cited 2×
“The prevalence of NAFLD in the general population increases with age; from 1 to 3% in children [32], 5% in teenagers [32, 33], 18% between 20 and 40 years, 39% in those aged 40 to 50 years, and to over 40% in those greater than 70 years [4, 26, 30, 34, 35].”
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“Relevant factors include age (especially over age 50 years), BMI > 28–32 kg/m2, insulin resistance or T2D, and raised serum ALT [13, 14, 27, 57, 85–91].”
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Powell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473 · cited 1×
“Additionally, more severe grades of baseline steatosis, elevated serum alanine aminotransferase (ALT), platelet count, and weight gain greater than 5 kg were other predictors of disease progression [53, 54].”
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360 · cited 1×
“In multivariate analysis, age, BMI, arterial hypertension, ALT, insulin resistance, and hepatic necroinflammatory grade were shown to independently predict presence of fibrosis [27, 36, 57, 86, 87, 89, 91].”
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322 · cited 1×
“A recent study of 246 biopsy-proven NAFLD patients from Hong Kong and France suggested decreasing ability to successfully obtain liver stiffness measurements (LSM) with increasing BMI; measurement was 97% successful with BMI < 30 kg/m2, dropping to only 75% in obese patients, though this did not reach statistical sign…”
Mofrad, P., Contos, M. J., Haque, M., Sargeant, C., Fisher, R. A., Luketic, V. A., Sterling, R. K., Shiffman, M. L., Stravitz, R. T., & Sanyal, A. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50229 · Cited by 1,201 · cited 1×
“Serum ALT increase is not only insensitive, but also nonspecific; values may remain within the normal range in up to 80% of patients with biopsy-proven NAFLD and up to 30% of NASH [19].”
Fatty acid-induced β cell apoptosis: A link between obesity and diabetes
Shimabukuro, M., Zhou, Y.-T., Levi, M., & Unger, R. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2498 · Cited by 1,142 · cited 1×
“Lipotoxicity is also favoured as the major pathway for pancreatic beta cell injury in T2D [62–66] and as part of the process of atherogenesis and cardiac toxicity with metabolic syndrome [62].”
Weight loss, exercise, or both and physical function in obese older adults
Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008234 · Cited by 1,096 · cited 1×
“In one study, a 21% improvement in physical performance measures was observed in the diet-exercise group as compared to 12% and 15% in the diet alone and exercise alone groups, respectively [94].”
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · cited 1×
“Insulin resistance in adipose tissue allows inappropriately sustained lipolysis with release of FFA, which are shunted to the liver at times when the liver is programmed for lipogenesis rather than for fat disposal [66].”
Liver fibrosis in overweight patients
Ratziu, V., Giral, P., Charlotte, F., Bruckert, E., Thibault, V., Theodorou, I., Khalil, L., Turpin, G., Opolon, P., & Poynard, T. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70364-7 · Cited by 973 · cited 1×
“In multivariate analysis, age, BMI, arterial hypertension, ALT, insulin resistance, and hepatic necroinflammatory grade were shown to independently predict presence of fibrosis [27, 36, 57, 86, 87, 89, 91].”
Lumeng, C. N., DelProposto, J. B., Westcott, D. J., & Saltiel, A. R. (2008) · Diabetes · doi:10.2337/db08-0872 · Cited by 917 · cited 1×
“This results from increased recruitment of inflammatory cells, particularly macrophages [73] in the setting of stressed and hypertrophic adipocytes caused by overnutrition and obesity [74].”
Adams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911 · cited 1×
“Both obesity and BMI were predictive of disease progression [55, 56].”
Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis
Yamauchi, T., Kamon, J., Waki, H., Imai, Y., Shimozawa, N., Hioki, K., Uchida, S., Ito, Y., Takakuwa, K., Matsui, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209033200 · Cited by 911 · cited 1×
“Similarly, in ob/ob (leptin deficient) mice, which are hyperphagic, develop insulin resistance and have severe steatosis [48], an adiponectin transgene (which restored normal serum adiponectin levels) expanded subcutaneous adipose and worsened obesity, but improved metabolic indices, such as glycemic control, in assoc…”
Age-related changes in total and regional fat distribution
Kuk, J. L., Saunders, T. J., Davidson, L. E., & Ross, R. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.06.001 · Cited by 778 · cited 2×
“Not surprisingly, anthropometric indices such as body mass index (BMI) and waist circumference do not accurately reflect total and regional adiposity as well as they do in younger patients [46].”
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751 · cited 1×
“In NAFLD, the TZDs have been shown to reduce serum ALT levels and hepatic steatosis, with some effects on necroinflammation activity, but effects on hepatic fibrosis have not usually been observed; this could relate to short duration of use, typically 6–12 months [106–109].”
The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective
Lazo, M., & Clark, J. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091978 · Cited by 736 · cited 2×
“In the elderly population, TE is a promising noninvasive method of quantifying liver fibrosis in NAFLD.”
Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver
Rafiq, N., Bai, C., Fang, Y., Srishord, M., McCullough, A., Gramlich, T., & Younossi, Z. M. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.11.005 · Cited by 729 · cited 2×
“2009 [77]”
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
Dixon, J. B., Bhathal, P. S., Hughes, N. R., & O'Brien, P. E. (2004) · Hepatology · doi:10.1002/hep.20251 · Cited by 727 · cited 1×
“With respect to NAFLD/NASH, follow-up liver biopsies have shown a reduction in hepatic necroinflammatory activity including resolution of NASH in the majority of cases and reduced hepatic fibrosis in some [119, 120].”
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726 · cited 1×
“In NAFLD, the TZDs have been shown to reduce serum ALT levels and hepatic steatosis, with some effects on necroinflammation activity, but effects on hepatic fibrosis have not usually been observed; this could relate to short duration of use, typically 6–12 months [106–109].”
Beneficial Effects of Subcutaneous Fat Transplantation on Metabolism
Tran, T. T., Yamamoto, Y., Gesta, S., & Kahn, C. R. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.004 · Cited by 703 · cited 2×
“This indicates possible intrinsic physiological difference in the adipocytes between the two sites [47].”
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Etiopathogenesis of Nonalcoholic Steatohepatitis
Chitturi, S., & Farrell, G. C. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-12927 · Cited by 661 · cited 1×
“NASH is now conceptualized as part of a pathological spectrum of a fatty liver disorders caused by metabolic factors and referred to collectively as nonalcoholic fatty liver disease (NAFLD).”
Self-citationIncreased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
Ong, J. P., Pitts, A., & Younossi, Z. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.018 · Cited by 638 · cited 2×
“The risk of liver-related death is even higher in the subgroup of patients with NASH compared to those with SS (2–10% for NASH versus 0–2% for SS) (Table 2) [57, 75–77].”
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
Ueno, T., Sugawara, H., Sujaku, K., Hashimoto, O., Tsuji, R., Tamaki, S., Torimura, T., Inuzuka, S., Sata, M., & Tanikawa, K. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80287-5 · Cited by 609 · cited 1×
“On the other hand, any effects on hepatic inflammation and fibrosis have been inconclusive [98].”
Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease
Malhi, H., & Gores, G. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091980 · Cited by 538 · cited 3×
“Thus, a more encompassing concept about NASH pathogenesis considers that the profile of lipid molecules in NASH differs from that of simple steatosis, acknowledging that TG is a nontoxic safe storage form of lipid in tissues such as the liver but that other molecules (candidates include free fatty acids (FFA), toxic s…”
Larson-Meyer, D. E., Heilbronn, L. K., Redman, L. M., Newcomer, B. R., Frisard, M. I., Anton, S., Smith, S. R., Alfonso, A., Ravussin, E., & the Pennington CALERIE Team (2006) · Diabetes Care · doi:10.2337/dc05-2565 · Cited by 504 · cited 1×
“7 kg in a 75 kg man) decreases liver fat by 40% in both nondiabetic and diabetic subjects [60, 95].”
Epidemiology of non-alcoholic fatty liver disease in China
Fan, J.-G., & Farrell, G. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.010 · Cited by 502 · cited 2×
“Hepatic steatosis (defined as greater than 5.5% TG content) was noted in 31% overall, with significant ethnic variation—45% in hispanics, 33% in whites, and 24% in blacks [28].”
InfluentialSelf-citationThe natural history of nonalcoholic fatty liver disease: a clinical histopathological study
Harrison, S. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00622-1 · Cited by 482 · cited 1×
“Additionally, more severe grades of baseline steatosis, elevated serum alanine aminotransferase (ALT), platelet count, and weight gain greater than 5 kg were other predictors of disease progression [53, 54].”
Mechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease
Jou, J., Choi, S., & Diehl, A. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091981 · Cited by 482 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis associated with metabolic abnormalities such as overweight/central obesity, insulin resistance, type 2 diabetes (T2D), and dyslipidemia.”
Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies
Fassio, E., �lvarez, E., Dom�nguez, N., Landeira, G., & Longo, C. (2004) · Hepatology · doi:10.1002/hep.20410 · Cited by 469
Sanyal, A. J., Mofrad, P. S., Contos, M. J., Sargeant, C., Luketic, V. A., Sterling, R. K., Stravitz, R. T., Shiffman, M. L., Clore, J., & Mills, A. S. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00457-4 · Cited by 437 · cited 1×
“In NAFLD, the TZDs have been shown to reduce serum ALT levels and hepatic steatosis, with some effects on necroinflammation activity, but effects on hepatic fibrosis have not usually been observed; this could relate to short duration of use, typically 6–12 months [106–109].”
Long–Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis C
Hui, J. M., Kench, J. G., Chitturi, S., Sud, A., Farrell, G. C., Byth, K., Hall, P., Khan, M., & George, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50320 · Cited by 437 · cited 1×
“If the person is cirrhotic at time of diagnosis, the risk of developing portal hypertension as a major complication is also high; 17%, 23%, and 52% at 1, 3, and 10 years, respectively [84].”
Self-citationBariatric Surgery for Morbid Obesity
DeMaria, E. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmct067019 · Cited by 427
Berson, A., De Beco, V., Lettéron, P., Robin, M. A., Moreau, C., Kahwaji, J. E., Verthier, N., Feldmann, G., Fromenty, B., & Pessayre, D. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70590-6 · Cited by 405 · cited 1×
“hepatocyte TG accumulation resulting from metabolic imbalance (obesity, IR and diabetes) is what leads to steatosis (the “first hit”) and that the lipid-laden liver is then vulnerable to injurious processes (“second hit” insults) such as cytokines and oxidative stress [58, 59].”
Metformin in the treatment of patients with non‐alcoholic steatohepatitis
Uygun, A., Kadayifci, A., Isik, A. T., Ozgurtas, T., Deveci, S., Tuzun, A., Yesilova, Z., Gulsen, M., & Dagalp, K. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01888.x · Cited by 405
Amarapurkar, D. N., Hashimoto, E., Lesmana, L. A., Sollano, J. D., Chen, P., Goh, K., & NAFLD, F. T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05042.x · Cited by 395 · cited 1×
“In the elderly population, TE is a promising noninvasive method of quantifying liver fibrosis in NAFLD.”
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394 · cited 1×
“In NAFLD, the TZDs have been shown to reduce serum ALT levels and hepatic steatosis, with some effects on necroinflammation activity, but effects on hepatic fibrosis have not usually been observed; this could relate to short duration of use, typically 6–12 months [106–109].”
Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
Argo, C. K., & Caldwell, S. H. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.005 · Cited by 389 · cited 5×
“In the earlier study, Kagansky et al. adopted US and CT scan as diagnostic modality for NAFLD, while Frith et al. used liver biopsies.”
InfluentialO'Brien, P. E., Dixon, J. B., Brown, W., Schachter, L. M., Chapman, L., Burn, A. J., Dixon, M. E., Scheinkestel, C., Halket, C., Sutherland, L. J., et al. (2002) · Obesity Surgery · doi:10.1381/096089202321019639 · Cited by 380 · cited 1×
“All other types of bariatric surgical techniques can decrease excess body weight by up to 50%, with generally less weight loss in laparoscopic procedures versus more invasive approaches [115–118].”
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02025.x · Cited by 369 · cited 1×
“Early studies of metformin in NASH showed significant reduction in hepatic steatosis and ALT, but histologic follow-up data are scarce and have not shown improvement in hepatic necroinflammatory grades [101–103], except in one study where it correlated with the degree of weight loss [101].”
Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366 · cited 1×
“Disappointingly, even though rosiglitazone substantially improved steatosis in the first year, longer treatment did not improve NASH histology despite maintained effects on insulin sensitivity and ALT levels [110].”
Prevalence of fatty liver in a general population of Okinawa, Japan.
NOMURA, H., KASHIWAGI, S., HAYASHI, J., KAJIYAMA, W., TANI, S., & GOTO, M. (1988) · Japanese Journal of Medicine · doi:10.2169/internalmedicine1962.27.142 · Cited by 355
Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis
Kral, J. G., Thung, S. N., Biron, S., Hould, F.-S., Lebel, S., Marceau, S., Simard, S., & Marceau, P. (2004) · Surgery · doi:10.1016/j.surg.2003.10.003 · Cited by 322 · cited 1×
“With respect to NAFLD/NASH, follow-up liver biopsies have shown a reduction in hepatic necroinflammatory activity including resolution of NASH in the majority of cases and reduced hepatic fibrosis in some [119, 120].”
Chen, C.-H., Huang, M.-H., Yang, J.-C., Nien, C.-K., Yang, C.-C., Yeh, Y.-H., & Yueh, S.-K. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200609000-00016 · Cited by 294 · cited 1×
“The weakness of the Kagansky study was reliance on clinical examination for detection of advanced liver disease, which has very low sensitivity especially in the absence of decompensated cirrhosis [38].”
Non-Alcoholic Fatty Liver Disease in Older People
Frith, J., Day, C. P., Henderson, E., Burt, A. D., & Newton, J. L. (2009) · Gerontology · doi:10.1159/000235677 · Cited by 282 · cited 1×
“A recent study in predominantly middle-aged American employees or outpatients (without known liver disease) found that the prevalence of steatosis by ultrasonography was 47%; in this study, NASH was confirmed histologically in 12% of the total cohort or 30% of the ultrasoundpositive subgroup [27].”
Role of Insulin Resistance and Lipotoxicity in Non-Alcoholic Steatohepatitis
Cusi, K. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.009 · Cited by 266
Hepatic Microcirculation in Fatty Liver Disease
Farrell, G. C., Teoh, N. C., & Mccuskey, R. S. (2008) · The Anatomical Record · doi:10.1002/ar.20715 · Cited by 266 · cited 2×
“As liver injury and cell death progresses, fat laden hepatocytes and perisinusoidal fibrosis may impair microvascular hepatic blood flow, causing decreased oxygen and nutrient exchange, and thereby stimulating microvascular inflammatory response and a self-perpetuating cycle of liver damage and vascular insufficiency…”
Self-citationGarcia-Monzón, C., Martín-Pérez, E., Iacono, O. L., Fernández-Bermejo, M., Majano, P. L., Apolinario, A., Larrañaga, E., & Moreno-Otero, R. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80301-3 · Cited by 265
Prevalence, gender, ethnic variations, and prognosis of NASH
Hashimoto, E., & Tokushige, K. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-010-0311-8 · Cited by 264 · cited 3×
“Hepatic steatosis (defined as greater than 5.5% TG content) was noted in 31% overall, with significant ethnic variation—45% in hispanics, 33% in whites, and 24% in blacks [28].”
InfluentialHepatic triglyceride synthesis and nonalcoholic fatty liver disease
Choi, S. S., & Diehl, A. M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ff5e55 · Cited by 255 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) is hepatic steatosis associated with metabolic abnormalities such as overweight/central obesity, insulin resistance, type 2 diabetes (T2D), and dyslipidemia.”
Exercise and risk factors associated with metabolic syndrome in older adults
Stewart, K. J., Bacher, A. C., Turner, K., Lim, J. G., Hees, P. S., Shapiro, E. P., Tayback, M., & Ouyang, P. (2005) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2004.09.006 · Cited by 255 · cited 1×
“Moreover, aerobic exercise reduces hepatic fat content independent of weight loss [96].”
Clinical Correlates of Histopathology in Pediatric Nonalcoholic Steatohepatitis
Patton, H. M., Lavine, J. E., Van Natta, M. L., Schwimmer, J. B., Kleiner, D., & Molleston, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.050 · Cited by 243 · cited 1×
“Over the last decade, communitybased studies have found male predominance of NAFLD from the paediatric population [6] up to fifth decade of life in adults.”
Obesity, diabetes mellitus, and liver fibrosis
Chiang, D. J., Pritchard, M. T., & Nagy, L. E. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00426.2010 · Cited by 236 · cited 3×
“In particular, central (or visceral) adiposity is strongly implicated in the development of both hepatic steatosis and metabolic syndrome [17, 60, 70].”
Bariatric surgery: Mechanisms, indications and outcomes
O'Brien, P. E. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06391.x · Cited by 214 · cited 1×
“All other types of bariatric surgical techniques can decrease excess body weight by up to 50%, with generally less weight loss in laparoscopic procedures versus more invasive approaches [115–118].”
De Lédinghen, V., Vergniol, J., Foucher, J., El-Hajbi, F., Merrouche, W., & Rigalleau, V. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02258.x · Cited by 205 · cited 1×
“However, the recent introduction of the “obese” probe allows LSM to be successfully increased from 45% to 76% in the morbidly obese (mean BMI > 40 kg/m2) [24].”
Non‐alcoholic fatty liver disease from pathogenesis to management: an update
Musso, G., Gambino, R., & Cassader, M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00657.x · Cited by 196 · cited 1×
“An approach to the management of NASH and its complications in the elderly, will also be presented here.”
Shah, K., Stufflebam, A., Hilton, T. N., Sinacore, D. R., Klein, S., & Villareal, D. T. (2009) · Obesity · doi:10.1038/oby.2009.126 · Cited by 194 · cited 1×
“In individuals aged over 65 years, the beneficial effect of diet and exercise on physical fitness, muscle strength [99], and metabolic fitness as shown by reduction in hepatic steatosis, serum cholesterol, high blood pressure, and improved insulin sensitivity Shah et al.”
Aging and the Liver: An Update
Schmucker, D. L. (1998) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/53a.5.b315 · Cited by 190 · cited 3×
“The octogenarian liver also has fewer, but larger, hepatocytes, increased polyploidy, and higher binuclear index [44], as well as a reduction in mitochondria numbers.”
Fatty liver and the metabolic syndrome among Shanghai adults
FAN, J., ZHU, J., LI, X., CHEN, L., LU, Y., LI, L., DAI, F., LI, F., & CHEN, S. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.04058.x · Cited by 186 · cited 2×
“An approach to the management of NASH and its complications in the elderly, will also be presented here.”
InfluentialCurrent concepts in the pathogenesis of nonalcoholic fatty liver disease
Méndez‐Sánchez, N., Arrese, M., Zamora‐Valdés, D., & Uribe, M. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01483.x · Cited by 184
A fresh look at NASH pathogenesis. Part 1: The metabolic movers
Larter, C. Z., Chitturi, S., Heydet, D., & Farrell, G. C. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06253.x · Cited by 180 · cited 2×
“An approach to the management of NASH and its complications in the elderly, will also be presented here.”
Self-citationAdipocytokines and liver disease
Kamada, Y., Takehara, T., & Hayashi, N. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2213-6 · Cited by 165 · cited 1×
“This results from increased recruitment of inflammatory cells, particularly macrophages [73] in the setting of stressed and hypertrophic adipocytes caused by overnutrition and obesity [74].”
Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground
Chitturi, S., Wong, V. W., & Farrell, G. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06548.x · Cited by 160 · cited 1×
“Although simple steatosis is generally nonprogressive [83], the initial assessment of SS as always being benign is not fully supported by current evidence [53–56].”
Self-citationVisceral adipose tissue area is an independent risk factor for hepatic steatosis
Park, B. J., Kim, Y. J., Kim, D. H., Kim, W., Jung, Y. J., Yoon, J. H., Kim, C. Y., Cho, Y. M., Kim, S. H., Lee, K. B., et al. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05212.x · Cited by 154 · cited 1×
“In particular, central (or visceral) adiposity is strongly implicated in the development of both hepatic steatosis and metabolic syndrome [17, 60, 70].”
Significant correlations between severe fatty liver and risk factors for metabolic syndrome
Hsiao, P., Kuo, K., Shin, S., Yang, Y., Lin, W., Yang, J., Chiu, C., Chuang, W., Tsai, T., & Yu, M. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04698.x · Cited by 152 · cited 1×
“An approach to the management of NASH and its complications in the elderly, will also be presented here.”
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease
Gramlich, T. L., Kleiner, D. E., McCullough, A. J., Matteoni, C. A., Boparai, N., & Younossi, Z. M. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.09.018 · Cited by 151 · cited 1×
“Relevant factors include age (especially over age 50 years), BMI > 28–32 kg/m2, insulin resistance or T2D, and raised serum ALT [13, 14, 27, 57, 85–91].”
The epidemiology of fatty liver
Bellentani, S., Bedogni, G., Miglioli, L., & Tiribelli, C. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200411000-00002 · Cited by 142 · cited 1×
“There are currently 2 epidemiological studies that have reported on fatty liver in individuals over 70 years.”
Outcomes of Bariatric Surgery in the Elderly
Varela, J. E., Wilson, S. E., & Nguyen, N. T. (2006) · The American Surgeon™ · doi:10.1177/000313480607201005 · Cited by 127 · cited 1×
“However, with the exception of a small subset of patients with significant heart disease, there is no significant difference in the observed-to-expected mortality ratio [121].”
Apoptosis and Cytokines in Non-Alcoholic Steatohepatitis
Syn, W.-K., Choi, S. S., & Diehl, A. M. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.003 · Cited by 125 · cited 2×
“However, aberrant repair in some individuals eventually leads to activation of hepatic stellate cells (HSC) to myofibroblasts and hepatic recruitment of proinflammatory and profibrogenic immune cells to the liver [61].”
Cheung, O., Kapoor, A., Puri, P., Sistrun, S., Luketic, V. A., Sargeant, C. C., Contos, M. J., Shiffman, M. L., Stravitz, R. T., Sterling, R. K., et al. (2007) · Hepatology · doi:10.1002/hep.21803 · Cited by 125 · cited 1×
“Clinical studies have also highlighted the adverse contribution of visceral adipose tissue (VAT) to the metabolic and liver complications of overweight/obesity [48, 71].”
Yamada, T., Fukatsu, M., Suzuki, S., Wada, T., Yoshida, T., & Joh, T. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05998.x · Cited by 113 · cited 1×
“The weakness of the Kagansky study was reliance on clinical examination for detection of advanced liver disease, which has very low sensitivity especially in the absence of decompensated cirrhosis [38].”
Wong, V. W., & Chan, H. L. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06437.x · Cited by 109
Petta, S., Amato, M., Cabibi, D., Cammà, C., Di Marco, V., Giordano, C., Galluzzo, A., & Craxì, A. (2010) · Hepatology · doi:10.1002/hep.23859 · Cited by 108 · cited 3×
“Similarly, in ob/ob (leptin deficient) mice, which are hyperphagic, develop insulin resistance and have severe steatosis [48], an adiponectin transgene (which restored normal serum adiponectin levels) expanded subcutaneous adipose and worsened obesity, but improved metabolic indices, such as glycemic control, in assoc…”
Review: Treatment options for nonalcoholic fatty liver disease
Lam, B., & Younossi, Z. M. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09359964 · Cited by 108
LIVER TRANSPLANTATION IN PATIENTS OVER SIXTY YEARS OF AGE
Garcia, C. E., Garcia, R. F. L., Mayer, A., & Neuberger, J. (2001) · Transplantation · doi:10.1097/00007890-200108270-00021 · Cited by 106 · cited 2×
“By 1999, 21% of liver transplant recipients were in people aged 60 years or older [123, 124].”
Chronic liver disease in an ageing population
Frith, J., Jones, D., & Newton, J. L. (2008) · Age and Ageing · doi:10.1093/ageing/afn242 · Cited by 106 · cited 1×
“Between the ages of 20 and 70, there is a decline in hepatic blood flow (by 33%), hepatic volume (up to 25%), and liver function [43].”
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan
Okanoue, T., Umemura, A., Yasui, K., & Itoh, Y. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06547.x · Cited by 105 · cited 3×
“In the Dallas Heart Study, Browning et al. used proton magnetic resonance spectroscopy (MRS) to quantify hepatic triglyceride (TG) content of 3 major ethnic groups.”
YILMAZ, Y. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04148.x · Cited by 94 · cited 1×
“What Drives Progression to Steatohepatitis (NASH) Once Steatosis Occurs? Significant hepatocyte apoptosis is a feature of NASH and forms the basis of a serum test for caspase3generated cytokeratin-18 fragments (a biomarker of apoptosis), which is being increasingly used to differentiate between patients with NASH and…”
Yoneda, M., Nozaki, Y., Endo, H., Mawatari, H., Iida, H., Fujita, K., Yoneda, K., Takahashi, H., Kirikoshi, H., Inamori, M., et al. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0771-y · Cited by 89 · cited 1×
“Similarly, serum ferritin is a nonspecific inflammatory marker, but while it is not specific for diagnosis of NAFLD, once the diagnosis has been established, serum ferritin has been shown to be significantly more elevated in patients with NASH compared with those with simple steatosis (SS) [20].”
Non‐alcoholic fatty liver disease – a common and benign finding in octogenarian patients
Kagansky, N., Levy, S., Keter, D., Rimon, E., Taiba, Z., Fridman, Z., Berger, D., Knobler, H., & Malnick, S. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0969.x · Cited by 86 · cited 1×
“In the Dallas Heart Study, Browning et al. used proton magnetic resonance spectroscopy (MRS) to quantify hepatic triglyceride (TG) content of 3 major ethnic groups.”
Clinical Aspects of Fatty Liver Disease
Choudhury, J., & Sanyal, A. J. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-860864 · Cited by 82 · cited 1×
“Further, reported studies of NASH prevalence may suffer from selection and ascertainment biases as liver biopsies were often performed in specific groups like the morbidly obese and diabetics or among highly selected subjects enrolled in clinical trials [21].”
Tobari, M., Hashimoto, E., Yatsuji, S., Torii, N., & Shiratori, K. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.1869 · Cited by 77 · cited 1×
“All noninvasive methods for diagnosis of NAFLD have limitations—computerised tomography (CT) scan and hepatic ultrasonography (US) are relatively insensitive; they can only detect moderate to severe steatosis [5, 18].”
Miyaaki, H., Ichikawa, T., Nakao, K., Yatsuhashi, H., Furukawa, R., Ohba, K., Omagari, K., Kusumoto, Y., Yanagi, K., Inoue, O., et al. (2008) · Liver International · doi:10.1111/j.1478-3231.2007.01614.x · Cited by 75 · cited 1×
“In multivariate analysis, age, BMI, arterial hypertension, ALT, insulin resistance, and hepatic necroinflammatory grade were shown to independently predict presence of fibrosis [27, 36, 57, 86, 87, 89, 91].”
Bariatric Surgery — Quick Fix or Long-Term Solution?
Solomon, C. G., & Dluhy, R. G. (2004) · New England Journal of Medicine · doi:10.1056/nejme048308 · Cited by 74
Effects of Weight Loss on Nonalcoholic Fatty Liver Disease
Rafiq, N., & Younossi, Z. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091986 · Cited by 71 · cited 2×
“This weight loss improves insulin sensitivity and reduces the frequency and severity of metabolic syndrome, diabetes and its complications [97].”
Tominaga, K., Fujimoto, E. K., Suzuki, K., Hayashi, M., Ichikawa, M., & Inaba, Y. (2009) · Environmental Health and Preventive Medicine · doi:10.1007/s12199-008-0074-5 · Cited by 70 · cited 1×
“Depending on the screening tool and when the study was performed, estimated community prevalence of NAFLD has ranged from 2.8% to 46% [25–27].”
InfluentialORTHOTOPIC LIVER TRANSPLANTATION IN PATIENTS OVER 60 YEARS OLD
Bromley, P. N., Hilmi, I. A., Tan, K. C., Williams, R. L., & Potter, D. (1994) · Transplantation · doi:10.1097/00007890-199410000-00009 · Cited by 59
Churilla, J. R., Fitzhugh, E. C., & Thompson, D. L. (2007) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2007.0010 · Cited by 58 · cited 1×
“Several studies have now shown increasing prevalence of the metabolic syndrome with advancing age [49, 50].”
Hellemans, K., Hannaert, J. C., Denys, B., Steffensen, K. R., Cindy, R., Martens, G. A., Veldhoven, P. P. V., Gustafsson, J.-Α., & PIPELEERS, D. G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007266 · Cited by 57 · cited 1×
“Lipotoxicity is also favoured as the major pathway for pancreatic beta cell injury in T2D [62–66] and as part of the process of atherogenesis and cardiac toxicity with metabolic syndrome [62].”
The liver and the waistline: Fifty years of growth
Farrell, G. C. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06080.x · Cited by 54 · cited 1×
“NASH is now conceptualized as part of a pathological spectrum of a fatty liver disorders caused by metabolic factors and referred to collectively as nonalcoholic fatty liver disease (NAFLD).”
Self-citationMetformin and serious adverse effects
Nisbet, J. C., Sturtevant, J. M., & Prins, J. B. (2004) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2004.tb05796.x · Cited by 51 · cited 1×
“The use of metformin in the elderly could be also problematic because of the additional risk of severe life-threatening lactic acidosis (5 per 100,000 prescriptions) [104].”
Elective hepatic resection in the elderly
Mentha, G., Huber, O., Róbert, J., Klopfenstein, C. E., Egeli, R., & Rohner, A. (1992) · British journal of surgery · doi:10.1002/bjs.1800790627 · Cited by 51 · cited 1×
“The ageing liver does appear to be more susceptible to the effects of drugs and other toxins, having diminished regenerative capacity to recover from insults, as evident by an increase in morbidity and mortality in hepatic resections in experimental studies in patients greater than 60 years old [44, 45].”
Tsuruta, G., Tanaka, N., Hongo, M., Komatsu, M., Horiuchi, A., Hamamoto, K., Iguchi, C., Nakayama, Y., Umemura, T., Ichijo, T., et al. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-009-0198-4 · Cited by 50 · cited 1×
“Depending on the screening tool and when the study was performed, estimated community prevalence of NAFLD has ranged from 2.8% to 46% [25–27].”
InfluentialFan, J., Li, F., Cai, X., Peng, Y., Ao, Q., & Gao, Y. T. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04892.x · Cited by 46 · cited 1×
“The weakness of the Kagansky study was reliance on clinical examination for detection of advanced liver disease, which has very low sensitivity especially in the absence of decompensated cirrhosis [38].”
Review article: the treatment of non‐alcoholic steatohepatitis with thiazolidinediones
Reynaert, H., Geerts, A. E., & Henrion, J. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02682.x · Cited by 45 · cited 1×
“Also, with regards to the older patient with NAFLD, TZDs can precipitate heart failure and their use is not recommended for patients with New York Heart Association Class III and IV heart failure [67, 111].”
Wasada, T., Kasahara, T., Wada, J., Jimba, S., Fujimaki, R., Nakagami, T., & Iwamoto, Y. (2008) · Metabolism · doi:10.1016/j.metabol.2008.02.015 · Cited by 44 · cited 1×
“An approach to the management of NASH and its complications in the elderly, will also be presented here.”
de Bruyn, G., & Graviss, E. A. (2001) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-1-6 · Cited by 43 · cited 1×
“These data are consistent with the clinical observation that NAFLD is now the commonest liver disorder seen in liver clinics of Western industrialised countries [4].”
Fatty acids and β-cell toxicity
Morgan, N. G. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328321e423 · Cited by 43
Visceral and Subcutaneous Adiposity and Adiponectin in Middle‐aged Japanese Men: The ERA JUMP Study
Nakamura, Y., Sekikawa, A., Kadowaki, T., Kadota, A., Kadowaki, S., Maegawa, H., Kita, Y., Evans, R. W., Edmundowicz, D., Curb, J. D., et al. (2009) · Obesity · doi:10.1038/oby.2009.3 · Cited by 37 · cited 1×
“Ageing can alter some of these modulators, such as by changes in SAT/VAT distribution with its effect on adiponectin levels [82], reduced liver blood flow, and reduced ability of ageing liver to adapt to injury.”
Fatty Liver and Liver Transplantation
Koehler, E. M., Watt, K. D. S., & Charlton, M. (2009) · Clinics in Liver Disease · doi:10.1016/j.cld.2009.07.010 · Cited by 37 · cited 2×
“Additionally, morbidly obese patients carry a high perioperative risk and are at increased risk for recurrence of progressive fatty liver disease after transplantation, especially in the setting of immunosuppressive therapy; hepatic steatosis occurs in up to 60% of transplant recipients, with 5–10% progressing to cirr…”
Prevention and treatment of nonalcoholic fatty liver disease
Targher, G., Bellis, A., Fornengo, P., Ciaravella, M. F., Pichiri, I., Perin, P. C., Trimarco, B., & Marchesini, G. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.02.004 · Cited by 27 · cited 1×
“In these programs, individuals are educated to self-manage their diet and to undertake moderate daily physical activity [92, 93].”
The health care information directive
Upshur, R. E. G., & Goel, V. (2001) · BMC Medical Informatics and Decision Making · doi:10.1186/1472-6947-1-1 · Cited by 26
Update on the metabolic syndrome: Hypertension
Reynolds, K., & Wildman, R. P. (2009) · Current Hypertension Reports · doi:10.1007/s11906-009-0026-5 · Cited by 19 · cited 1×
“Several studies have now shown increasing prevalence of the metabolic syndrome with advancing age [49, 50].”
Management of nonalcoholic fatty liver disease: weight control
Bouneva, I., & Kirby, D. F. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.003 · Cited by 16 · cited 1×
“In these programs, individuals are educated to self-manage their diet and to undertake moderate daily physical activity [92, 93].”
Frith, J., & Newton, J. L. (2009) · Maturitas · doi:10.1016/j.maturitas.2009.11.010 · Cited by 16 · cited 1×
“NAFLD pathology ranges from simple steatosis to a necroinflammatory fibrosing disorder called steatohepatitis (SH), the latter associated with high risk of developing cirrhosis, often occuring in the seventh to ninth decades of life.”
Review: Treatment options for nonalcoholic fatty liver disease
Chitturi, S. (2008) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08096951 · Cited by 13 · cited 2×
“Metformin causes weight reduction and improves insulin sensitivity by decreasing hepatic glucose output and increasing peripheral glucose uptake, reducing hepatic lipogenesis and increasing hepatic fatty acid β-oxidation (by activation of AMP-activated protein kinase), and suppression of lipogenic transcription factor…”
Self-citationLiu, C., Hung, C., Shih, S., Ko, H.-J., Lu, Y., Wu, Y., Cheng, H.-Y., Hu, K., Yeh, H., & Chang, R. (2010) · International journal of gerontology · doi:10.1016/j.ijge.2010.11.005 · Cited by 8 · cited 1×
“As discussed before, there is a very strong correlation between metabolic syndrome and the subsequent development of NAFLD conversely, presence of hepatic steatosis is predictive for development of metabolic syndrome [13, 25, 36, 51].”
Younossi, Z. M., Stepanova, M., Afendy, M., Fang, Y. H., Younossi, Y., Mir, H. M., & Srishord, M. K. (2011) · Journal of Hepatology · doi:10.1016/s0168-8278(11)60018-4 · Cited by 7
Nonalcoholic fatty liver disease in children
Dahshan, A., Chalmers, L. J., & Tolia, V. K. (2008) · Therapy · doi:10.2217/14750708.6.1.83 · Cited by 7
Cardiac effects of non-cardiac drugs
Hopper, I. (2011) · Australian Prescriber · doi:10.18773/austprescr.2011.030 · Cited by 6 · cited 2×
“Its access is restricted in Australia and America [113].”
Adiponectin as a therapeutic target of non‐alcoholic steatohepatitis
Shiota, G. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2009.00596.x · Cited by 4 · cited 1×
“The latter process is governed by several nuclear transcription factors that are activated by insulin (in the case of sterol regulatory element binding proteins (SREBP)1 and 2) and glucose (in the case of carbohydrate-responsive sterol regulatory element binding protein (ChREBP)1) [11, 12, 69].”
Research works printed but not linked: 8
- 2007, Metabolic Syndrome, 1
- 2011, Journal of Hepatology, 54, S8
- 1998, The Journals of Gerontology Series A, 53, B315
- 10.1111/j.1572-0241.2003.07659.x · doi:10.1111/j.1572-0241.2003.07659.x · Paper page
- 10.1172/JCI200523621 · DOI · Paper page
- 2007, Cochrane Database of Systematic Reviews
- 10.1016/S0002-9270(00)02346-7 · doi:10.1016/s0002-9270(00)02346-7 · Paper page
- 10.1053/jhep.2003.50420 · doi:10.1053/jhep.2003.50420 · Paper page
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
“Both autophagic and CMA activity are impaired with aging, leading to lipid accumulation in various organs, including the liver.310 Furthermore, the accumulation of damaged mitochondria is a hallmark of NASH.311 Mitophagy, a form of autophagy that selectively targets abnormal mitochondria for lysosomal degradation, is…”
BackgroundInfluentialMitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases
(2018) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.05.006 · Cited by 455
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Nonalcoholic fatty liver disease and aging: epidemiology to management.
Bertolotti, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14185 · Cited by 270
Mak, K. M., & Mei, R. (2017) · The Anatomical Record · doi:10.1002/ar.23567 · Cited by 269
“Codistribution of Col IV and Laminin as a Marker of Perisinusoidal Basement Membrane Formation in Liver Fibrosis of Elderly Cadavers Fibrotic changes are often seen in aged livers (Gan et al., 2011; Noureddin et al., 2013; Xu et al., 2013).”
Background
Metadata
- Authors
- Gan, L., Chitturi, S., & Farrell, G. C.
- Affiliations
- Australian National University (AU)
- Corresponding author
- Farrell, Geoffrey C.
- ORCID
- Chitturi, Shivakumar
- Venue
- Current Gerontology and Geriatrics Research
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-12
- ISSN
- 1687-7063 (ISSN-L)
- 1687-7071
- PMC
- PMC3171768
- OpenAlex
- W2023535895
- Cited by
- 135
- References
- 127
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 13 · 2023: 14 · 2022: 11 · 2021: 13 · 2020: 12 · 2019: 12 · 2018: 7 · 2017: 6 · 2016: 5 · 2015: 11 · 2014: 2 · 2013: 6 · 2012: 5
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Current Gerontology and Geriatrics Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ANU Open Research (Australian National University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, aging, older adults, hepatic steatosis, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, type 2 diabetes, insulin resistance, metabolic abnormalities, mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.